Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J.L., Schirmacher, P. and Vilgrain, V. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
https://doi.org/10.1016/j.jhep.2018.03.019

has been cited by the following article:

• TITLE: Research Progress on the Prediction of TACE Efficacy by Lipiodol Deposition

  AUTHORS: Yi Qing, Yong Li

  KEYWORDS: Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Lipiodol, Interventional Treatment

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.11, November 21, 2023

  ABSTRACT: Primary hepatocellular carcinoma is one of the most common and deadliest malignant tumors in the world, and most patients are diagnosed after missing the optimal treatment period. TACE (Transcatheter arterial chemoembolization) is currently the preferred treatment for advanced HCC (Hepatocellular Carcinoma), as it can induce local ischemic necrosis of the tumor while reducing the systemic side effects of drugs by embolizing the tumor-feeding arteries. Lipiodol, with its unique comprehensive properties of imaging, drug loading, and embolization, has become a key component in the process of TACE. Therefore, analyzing the deposition of lipiodol in hepatic tumor tissues after TACE can effectively evaluate the treatment efficacy. This article summarizes and analyzes the metabolism of lipiodol in tumors and the clinical application of lipiodol deposition status in predicting patient prognosis, aiming to provide clearer diagnostic and treatment strategies for clinical doctors.